# SYNTRIX BIOSYSTEMS, INC.: A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | SYNTRIX BIOSYSTEMS, INC. |
| Location | AUBURN, WA |
| Project | A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients |
| Project number | 1R44CA306688-01A1 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $406,500 |
| Awarded | 2026-09-14 |
| Project period | 2026-09-14 to 2027-08-31 |
| UEI | L5Z8K6ZE8LY4 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11406776). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.